The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; none of the 29 sources its claims cite is checked for support yet.
Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy
Open accessAbstract
Tumor-associated hypoxia plays an important role in carcinogenesis and metastasis. The expression, activation, and stabilization of hypoxia-inducible transcription factors (HIFs) support malignant cell survival, proliferation, plasticity, and motility. Hypoxia also upregulates the expression of programmed cell death ligand 1 (PD-L1) in malignant and immune regulatory cells. Therefore, the combination of HIF inhibitors and checkpoint inhibitors (CPIs) is promising for boosting antitumor immunity and diminishing malignant cell plasticity and therapy resistance. In this issue of the JCI, Salman et al. report the development of a specific agent that inhibited HIF-1/2-mediated gene expression in tumor cells and suppressed tumor growth. Bailey, Liu, et al. in this issue demonstrate that targeting HIF-1α abrogated PD-L1-mediated immune evasion by suppressing PD-L1 expression on malignant and myeloid regulatory cells, causing tumor rejection. These findings suggest that targeting the HIF/PD-L1 axis with specific HIF inhibitors should improve the safety and efficacy of CPIs for cancer therapy.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This JCI commentary reviews the cross-talk between hypoxia-inducible factors (HIFs) and the PD-1/PD-L1 axis in cancer, arguing that combining HIF inhibitors with checkpoint inhibitors (CPIs) could improve antitumor immunity and reduce therapy resistance. It highlights two companion JCI studies showing that HIF inhibition suppresses tumor growth and PD-L1–mediated immune evasion.
Key findings
- Hypoxia stabilizes HIF-1/HIF-2, which promote angiogenesis, immunosuppression, EMT, and metabolic reprogramming, and upregulate PD-L1 on malignant and myeloid regulatory cells; hypoxia correlates with worse prognosis and resistance to therapy.
- Salman et al. developed a low-molecular-weight agent inhibiting HIF-1/2–mediated gene expression that suppressed tumor growth in mice, reduced vascularization and immunosuppression (fewer TAMs and MDSCs via suppressed IL-4, IL-13, CXCL1), increased CTL/NK infiltration (via CXCL9/CXCL10), and raised the complete response rate to anti–PD-1 from 25% to 67%.
- Bailey, Liu, et al. showed that pharmaceutical or genetic HIF-1α targeting suppressed PD-L1 on malignant cells and myeloid regulatory cells, reactivated TILs, caused tumor rejection, downregulated PD-1, upregulated granzyme B and perforin, and potentiated anti–CTLA-4 therapy.
- Bailey, Liu, et al. also found that HIF-1α inhibition blocked PD-L1 at the tumor site but induced PD-L1 in normal tissues, suggesting a route to safer immunotherapy by differential PD-L1 regulation.
Methods
- Design: a commentary/review article in the Journal of Clinical Investigation discussing the HIF/PD-L1 axis and two companion studies published in the same issue.
- Data: no primary data; the article synthesizes published experimental and clinical literature (including refs. 1–25) and describes the findings of Salman et al. (ref. 23) and Bailey, Liu, et al. (ref. 24).
- Analysis: narrative synthesis of mechanisms and therapeutic implications, with a proposed framework for combining HIF inhibitors with CPIs.
Limitations
- Not stated in the paper (the commentary does not include a limitations section).
- Evident from the text: this is a commentary without original data, so its conclusions rest on the two cited companion studies and prior literature; the highlighted findings derive largely from murine tumor models, and the authors note that testing in different tumor models and understanding interactions with TGF-β, IL-1, hormones, and growth factors remain necessary.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 29 cited sources checked · 0 supported · 0 flagged
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These findings suggest that targeting the HIF/PD-L1 axis with specific HIF inhibitors should improve the safety and efficacy of CPIs for cancer therapy.”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > Abstract
Tests✓ Asserted: passes? Checkable: unclear✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: The murine tumor model results for HIF inhibitors and CPI combinations are predictive of human cancer therapy.
In the paper
“The expression, activation, and stabilization of hypoxia-inducible transcription factors (HIFs) support malignant cell survival, proliferation, plasticity, and motility.”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > Abstract
What the sources say
- Not checked yetcites [1] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Tumor-associated hypoxia plays an important role in carcinogenesis and metastasis.”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > Abstract
What the sources say
- Not checked yetcites [1] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“Hypoxia also upregulates the expression of programmed cell death ligand 1 (PD-L1) in malignant and immune regulatory cells.”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“HIF-1 promotes tumor progression via the stimulation of angiogenesis, immunosuppression, epithelial-mesenchymal transition (EMT), and metabolic reprogramming, supporting malignant cell survival, proliferation, plasticity, and motility (ref. 1 and Figure 1).”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > Hypoxia-inducible factors in cancer
What the sources say
- Not checked yetcites ref. 1
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Recent data indicate that hypoxia is also able to upregulate expression of PD-L1 in malignant cells via HIF-1α and HIF-2α (17).”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > Conclusions
What the sources say
- Not checked yetcites [17] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“For instance, analysis of the melanoma genome atlas data shows a correlation of the HIF-1 signaling signature with PD-L1 mRNA expression, especially with IFN-γ–induced expression of PD-L1 mRNA (25).”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > Conclusions
What the sources say
- Not checked yetcites [25] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“Importantly, HIF-1α inhibition synergizes with anti–PD-1 therapy to inhibit tumor development (Figure 1).”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > PD-L1/HIF cross-talk and therapeutic applicability
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Importantly, HIF-1α inhibition potentiated immunotherapeutic effects of anti–CTLA-4 therapy in experimental models.”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > PD-L1/HIF cross-talk and therapeutic applicability
What the sources say
- Not checked yetcites [24] Bailey, 2022, Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues, J Clin Invest source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Administration of the HIF inhibitor in tumor-bearing mice resulted in inhibition of tumor growth.”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > PD-L1/HIF cross-talk and therapeutic applicability
What the sources say
- Not checked yetcites [23] Salman, 2022, HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy, J Clin Invest source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 15
- Probably not a substantial claim. 3
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Therefore, the combination of HIF inhibitors and checkpoint inhibitors (CPIs) is promising for boosting antitumor immunity and diminishing malignant cell plasticity and therapy resistance.”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Bailey, Liu, et al. in this issue demonstrate that targeting HIF-1α abrogated PD-L1–mediated immune evasion by suppressing PD-L1 expression on malignant and myeloid regulatory cells, causing tumor rejection.”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > Abstract
What the sources say
- Not checked yetcites [24] Bailey, 2022, Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues, J Clin Invest source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Hence, in a clinical setting, hypoxia correlates with worse prognosis in different cancer types and, in addition, imparts resistance to different therapeutic approaches (4).”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > Hypoxia-inducible factors in cancer
What the sources say
- Not checked yetcites [4] Semenza, 2002, HIF-1 and tumor progression: pathophysiology and therapeutics, Trends Mol Med source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“In this issue of the JCI, Salman et al. report the development of a specific agent that inhibited HIF-1/2–mediated gene expression in tumor cells and suppressed tumor growth.”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > Abstract
What the sources say
- Not checked yetcites [23] Salman, 2022, HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy, J Clin Invest source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Clinical studies of HIF inhibitors indicate benefit and justify further evaluation either as a single agent or in combination with other antitumor agents (6).”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > Hypoxia-inducible factors in cancer
What the sources say
- Not checked yetcites [6] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In a murine melanoma model, inhibition of HIF-1α transcriptional activity results in CCL2- and CCL5-mediated increases in NK cells and CTLs in the tumor bed, and improves the antitumor potential of peptide vaccination and anti–PD-1 blocking antibody (22).”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > PD-L1/HIF cross-talk and therapeutic applicability
What the sources say
- Not checked yetcites [22] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Combination therapies based on PD-1/PD-L1 blockade for a wide range of cancer types have been introduced and can improve patient survival (20).”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > PD-1/PD-L1 axis in cancer
What the sources say
- Not checked yetcites [20] source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Inducible expression of PD-L1 at the tumor site is involved in cancer escape because its binding to PD-1 on effector T cells causes T cell exhaustion and apoptosis, while apoptosis of regulatory T cells is inhibited (19).”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > PD-1/PD-L1 axis in cancer
What the sources say
- Not checked yetcites [19] Han, 2020, PD-1/PD-L1 pathway: current researches in cancer, Am J Cancer Res
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“HIF-1α inhibition in vivo downregulated PD-1 expression, upregulated cytolytic effector molecules granzyme B and perforin, and decreased apoptosis in TILs in the tumor microenvironment.”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > PD-L1/HIF cross-talk and therapeutic applicability
What the sources say
- Not checked yetcites [24] Bailey, 2022, Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues, J Clin Invest source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Bailey, Liu, et al. confirmed these results (24).”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > Conclusions
What the sources say
- Not checked yetcites [24] Bailey, 2022, Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues, J Clin Invest source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Salman et al. also support the notion that highly specific and nontoxic HIF inhibitors deserve further investigation when applied alone or in combination with CPIs and other targeted therapy (23).”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > Conclusions
What the sources say
- Not checked yetcites [23] Salman, 2022, HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy, J Clin Invest source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
- Rests on an assumption: HIF inhibitors can be developed that are highly specific and nontoxic in humans.
In the paper
“The synthesized low-molecular-weight agent targeted both HIF-1 and HIF-2, inducing HIF-α subunit degradation and thus inhibiting activation of HIF-1– and HIF-2–target gene transcription.”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > PD-L1/HIF cross-talk and therapeutic applicability
What the sources say
- Not checked yetcites [23] Salman, 2022, HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy, J Clin Invest source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Numerous experimental and clinical data reveal that hypoxia induces radioresistance and resistance to a variety of chemotherapeutic agents, affects antitumoral immune responses, and controls crucial regulatory pathways, impacting key aspects of cancer biology.”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > Hypoxia-inducible factors in cancer
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“For instance, in vivo treatment with PX-478 and anti–PD-1 antibodies suppresses tumor growth and prolongs animal survival, which is associated with downregulation of EMT phenotypes, lower immunosuppression, and enhanced TIL homing (21).”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > PD-L1/HIF cross-talk and therapeutic applicability
What the sources say
- Not checked yetcites [21] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The authors also reported an interesting observation; although HIF-1α inhibition blocked PD-L1 expression at the tumor site, it induced PD-L1 in normal tissues.”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > PD-L1/HIF cross-talk and therapeutic applicability
What the sources say
- Not checked yetcites [24] Bailey, 2022, Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues, J Clin Invest source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In vivo alterations of the tumor immune environment involved fewer protumorigenic tumor-associated macrophages (TAMs) and MDSCs due to the suppression of IL-4, IL-13, and CXCL1 expression, and elevated infiltration by antitumor CTLs and NK cells attracted by elevated CXCL9 and CXCL10 levels.”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > PD-L1/HIF cross-talk and therapeutic applicability
What the sources say
- Not checked yetcites [23] Salman, 2022, HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy, J Clin Invest source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The smaller tumors were associated with lower tumor vascularization due to decreased expression of multiple genes encoding angiogenic factors, and lower immunosuppression due to diminished expression of genes encoding proteins mediating immunosuppression.”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > PD-L1/HIF cross-talk and therapeutic applicability
What the sources say
- Not checked yetcites [23] Salman, 2022, HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy, J Clin Invest source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The findings on differential regulation of PD-L1 expression by HIF suggest that a combination of HIF inhibition with some CPIs, like anti–CTLA-4, for example, should be experimentally verified.”
§ Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy > Conclusions
Tests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence.
The paper relies on this without support.
The murine tumor model results for HIF inhibitors and CPI combinations are predictive of human cancer therapy.
“These findings suggest that targeting the HIF/PD-L1 axis with specific HIF inhibitors should improve the safety and efficacy of CPIs for cancer therapy.”
The paper relies on this without support.
HIF inhibitors can be developed that are highly specific and nontoxic in humans.
“Salman et al. also support the notion that highly specific and nontoxic HIF inhibitors deserve further investigation when applied alone or in combination with CPIs and other targeted therapy (23).”
The paper relies on this without support.
HIF-1α inhibition-induced PD-L1 expression in normal tissues leads to immune tolerance in humans.
“Promotion of immune tolerance by differential regulation of PD-L1 in normal and cancer tissues is an important approach for safer and more successful immunotherapy (24).”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hypoxia can directly upregulate the expression of various cellular immune checkpoints (such as programmed cell death‐ligand 1, PD‐L1) in the TME.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [108]
Citations
Cites
1 retracted
Lee, K., Qian, D. Z., Rey, S., Wei, H., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812801106 · Cited by 289 · cited 4×
“For example, rapamycin can inhibit hypoxia-induced HIF-1α expression (4), while doxorubicin and daunorubicin inhibit HIF-1 by blocking its binding to DNA (12).”
BackgroundInfluentialRetractedNoman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166 · cited 8×
“Recent data indicate that hypoxia is also able to upregulate expression of PD-L1 in malignant cells via HIF-1α and HIF-2α (17).”
BackgroundInfluentialPD-1/PD-L1 pathway: current researches in cancer.
Han, Y., Liu, D., & Li, L. (2020) · PubMed Central · Cited by 1,602
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · cited 1×
“Combination therapies based on PD-1/PD-L1 blockade for a wide range of cancer types have been introduced and can improve patient survival (20).”
BackgroundHIF-1 and tumor progression: pathophysiology and therapeutics
Semenza, G. L. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02317-1 · Cited by 1,060 · cited 2×
“Hence, in a clinical setting, hypoxia correlates with worse prognosis in different cancer types and, in addition, imparts resistance to different therapeutic approaches (4).”
BackgroundHypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression
Semenza, G. L. (2000) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230091169186 · Cited by 657 · cited 1×
“Transient acute hypoxic conditions and chronic hypoxia generate a metabolically diverse tumor microenvironment (3), which induces an intense conditional pressure on cancerous cells that encourages the survival of aggressive malignant clones.”
BackgroundBerchem, G., Noman, M. Z., Bosseler, M., Paggetti, J., Baconnais, S., Cam, É. L., Nanbakhsh, A., Moussay, E., Mami‐Chouaib, F., Janji, B., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1062968 · Cited by 325 · cited 1×
“This suggestion is based on data showing that a hypoxic environment permits escape of cancerous cells from killing by cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells via granzyme B degradation and TGF-β– containing extracellular vesicles (15, 16).”
BackgroundKoh, M. Y., Spivak-Kroizman, T., Venturini, S., Welsh, S., Williams, R. R., Kirkpatrick, D. L., & Powis, G. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0463 · Cited by 309 · cited 1×
“PX-478, a melphalan derivative, lowers HIF-1α levels by inhibiting HIF1α deubiquitination, decreasing HIF-1α mRNA expression, and reducing HIF-1α translation (11).”
BackgroundHIF Inhibitors: Status of Current Clinical Development
Fallah, J., & Rini, B. I. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0752-z · Cited by 308 · cited 2×
“Alternatively, some approved drugs known to indirectly alter the HIF-1α pathway could also act as adjuvant therapy for existing cancer treatments (6).”
BackgroundDeng, J., Li, J., Sarde, A., Lines, J. L., Lee, Y.-C., Qian, D. C., Pechenick, D. A., Manivanh, R., Le Mercier, I., Lowrey, C. H., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0507 · Cited by 224
Flagged first, then by citations
1 of the 26 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–113 of 113
Regulation of PD-L1 Expression by SAHA-Mediated Histone Deacetylase Inhibition in Lung Cancer Cells
Natarajan, U., & Rathinavelu, A. (2025) · Cancers · doi:10.3390/cancers17172919 · Cited by 2
Li, M., Guo, T., Wang, Z., Liu, X., Guo, L., & Cao, L. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1744341 · Cited by 1
Convergence of immunometabolism and lung cancer therapy: redefining the tumor–immune interface
Zhu, H., Li, R., Wen, X., Luo, W., & Liu, Q. (2026) · European journal of medical research · doi:10.1186/s40001-026-04011-w
Hsia, Y., Lin, Z.-M., Tseng, T.-S., & Chou, T. (2026) · Antioxidants · doi:10.3390/antiox15040413
When protein stability drives tumor progression
Tabarkiewicz, J., Niedźwiedzka‐Rystwej, P., Tynecka, M., & Eljaszewicz, A. (2026) · Central European Journal of Immunology · doi:10.5114/ceji/221492
Yang, T., Chen, T., & Yang, R. (2026) · Molecular Genetics and Genomics · doi:10.1007/s00438-026-02461-9
“Moreover, HIF-1α can elevate PD-L1 levels within the hypoxic tumor micro-environment, enabling cancer cells to adapt to low-oxygen conditions and evade immune surveillance (Shurin and Umansky 2022 ).”
Regulation of PD-1 and PD-L1 expression in tumor immune microenvironment
Liu, P., Han, G., Chen, Z., & Wu, J. (2026) · Seminars in Oncology · doi:10.1016/j.seminoncol.2026.152522
Wang, Z., Tang, Y., Yue, R., Xu, J., Tao, Y., Chen, J., Li, S., Zhao, G., Xue, J., Sun, M., et al. (2026) · Advanced Science · doi:10.1002/advs.76780
“Accumulation of HIF-1 α can potentiate GLUT1-mediated glucose uptake and glycolytic flux while upregulating immune-evasion molecules such as PD-L1, ultimately establishing a vicious cycle in which ionic imbalance and glycolytic dysregulation reinforce one another [ 10–12 ].”
Qiao, C., Cheng, T., & 李俊生 (2026) · Methods · doi:10.1016/j.ymeth.2026.07.013
Carrero, Y. N., & Mosquera, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1922814
“…the extracellular matrix via metalloproteinases, generates a disorganized VEGF-dependent vasculature, and promotes lactic acidi fi cation of the microenvironment three mechanisms that collectively hinder the in fi ltration of effector lymphocytes and undermine antitumor immune surveillance (163).”
Wang, Y., Liu, M., & Zhong, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1991297
Ni, M., Zhou, L., Zhang, L., Su, Y., Shi, H., Chen, M., Zheng, Q., Li, H., Wang, D., Dun, S., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-016269
HIF-1α-mediated metabolic reprogramming in hypoxia-driven tumor metastasis
Shao, S., Wang, M., Xie, R., Liu, S., Dai, W., Zeng, T., Lai, L., Zhang, K., & Li, Y. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1997123
Metadata
- Authors
- Shurin, M. R., & Umansky, V.
- Affiliations
- University of Pittsburgh Medical Center (US)
- German Cancer Research Center (DE)
- Corresponding author
- Shurin, Michael R.
- Venue
- Journal of Clinical Investigation
- Published
- 2022-05-02
- Volume
- 132
- Issue
- 9
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC9057611
- OpenAlex
- W4225246674
- Semantic Scholar
- a20a1dd856629f2de755ae6db054bceeadf62ed8
- Cited by
- 113
- References
- 26
- Citations by year
- 2026: 26 · 2025: 27 · 2024: 31 · 2023: 24 · 2022: 5
- FWCI
- 9.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Pittsburgh
- Deutsches Krebsforschungszentrum
- Universität Heidelberg
- National Cancer Institute (P30CA047904)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- hypoxia-inducible factor, HIF-1α, PD-L1, PD-1/PD-L1 axis, tumor hypoxia, HIF inhibitors, immune checkpoint inhibitors, cancer immunotherapy, tumor immune evasion, treatment resistance, carcinogenesis, metastasis
- MeSH terms
- Hypoxia, Humans, Ligands, Neoplasms, Apoptosis, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
